Theratechnologies Annouces Commercialization Agreement for Egrifta (Tesamorelin for injection) in Europe
Theratechnologies Annouces Commercialization Agreement for Egrifta (Tesamorelin for injection) in Europe
Feb 27, 2015
Supporting Materials:
Theratechnologies Inc. (TSX: TH) is pleased to announce that it has concluded an agreement with AOP Orphan Pharmaceuticals AG (AOP) for the distribution and commercialization of EGRIFTATM in several European countries.